Related Experiment Video

Updated: May 3, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients?

Seung Tae Kim1, Kyong Hwa Park2, Sang Won Shin2

  • 1Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Cancer Research and Treatment
|February 13, 2014
PubMed
Abstract

Insights

KRAS mutations do not predict bevacizumab effectiveness or prognosis in metastatic colorectal cancer (CRC) patients receiving anti-VEGF therapy. This finding clarifies the role of KRAS in CRC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Research

Background:

  • KRAS mutations are established negative predictors for anti-EGFR therapies in metastatic colorectal cancer (CRC).
  • The predictive or prognostic value of KRAS mutations for anti-VEGF therapies in CRC remains controversial.

Purpose of the Study:

  • To investigate the role of KRAS mutation status as a predictive biomarker for bevacizumab efficacy in CRC patients.
  • To evaluate KRAS mutation status as a prognostic factor for overall survival (OS) in CRC patients treated with bevacizumab.

Main Methods:

  • Retrospective analysis of 32 CRC patients receiving first-line cytotoxic chemotherapy plus bevacizumab.
  • KRAS mutation status was determined and correlated with progression-free survival (PFS) and OS.
  • Univariate analysis was performed to assess the prognostic value of KRAS mutations.

Main Results:

  • KRAS mutations were observed in 59.4% of the patients.
  • No significant difference in PFS or OS was found between patients with and without KRAS mutations receiving bevacizumab-based chemotherapy.
  • KRAS mutations did not demonstrate significant prognostic value for PFS or OS in univariate analysis.

Conclusions:

  • KRAS mutation status is neither a predictive biomarker for bevacizumab efficacy nor a prognostic factor for OS in CRC patients treated with anti-VEGF therapy.
  • These findings suggest that KRAS mutation status should not guide the use of bevacizumab in CRC treatment.
Keywords:
Colonic neoplasmsKRASVascular endothelial growth factor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K